During the corresponding time, Veracyte Inc recorded a revenue increase by 23.45 % year on year, sequentially revenue grew by 12.05 %. While revenue at the Veracyte Inc 's corporate clients
Veracyte Inc's Comment on Sales, Marketing and Customers
The company provides test kits to customers who subsequently bill third-party payers for reimbursement. Its Prosigna test is reimbursed in multiple countries, including Germany, France, Spain, Portugal, Italy, the Netherlands, Norway, Sweden, Denmark, Austria, Lithuania, Switzerland, Canada, England, Scotland, and Israel. The company focuses on genomic biomarker testing in disease areas such as thyroid cancer (Afirma test), prostate cancer (Decipher Prostate test), bladder cancer, and minimal residual disease (MRD) for muscle-invasive bladder cancer (MIBC). It collaborates with specialist channels and partners to engage early in the cancer care continuum, spanning diagnosis, treatment, and monitoring.
Customers and markets referenced in company filings include ArteraAI, Billion-To-One, Caris Life Sciences, Exact Sciences Corporation, Guardant Health, Inc., Interpace Diagnostics Group, Inc., MDxHealth, SA, Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., Personalis, Quest Diagnostics, Sonic Healthcare Limited, and TempusAI, Inc.
Unveiling Genomic Insights: Veracyte s Prominent Role at the 2025 American Thyroid Association Annual Meeting In South San Francisco, a locus of innovation for oncology diagnostics, Veracyte, Inc. (Nasdaq: VCYT) prepares to take centre stage at the 2025 American Thyroid Association (ATA) Annual Meeting. This reputable congregation, scheduled from September 10th to 14th at the Westin Kierland, Scottsdale, Arizona, will showcase a plethora of academic and clinical insights into thyroid health, a domain where Veracyte has notably made its mark.Veracyte s principal focus lies in the functionality of the thyroid, a small gland with profound systemic significance. The company will present a substantial body of res...
Veracyte Inc’s Comment on Sales, Marketing and Customers
The company provides test kits to customers who subsequently bill third-party payers for reimbursement. Its Prosigna test is reimbursed in multiple countries, including Germany, France, Spain, Portugal, Italy, the Netherlands, Norway, Sweden, Denmark, Austria, Lithuania, Switzerland, Canada, England, Scotland, and Israel. The company focuses on genomic biomarker testing in disease areas such as thyroid cancer (Afirma test), prostate cancer (Decipher Prostate test), bladder cancer, and minimal residual disease (MRD) for muscle-invasive bladder cancer (MIBC). It collaborates with specialist channels and partners to engage early in the cancer care continuum, spanning diagnosis, treatment, and monitoring.
Customers and markets referenced in company filings include ArteraAI, Billion-To-One, Caris Life Sciences, Exact Sciences Corporation, Guardant Health, Inc., Interpace Diagnostics Group, Inc., MDxHealth, SA, Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., Personalis, Quest Diagnostics, Sonic Healthcare Limited, and TempusAI, Inc.
Sources:
Veracyte Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Veracyte Inc’s corporate clients.
For your research, we’ve provided 9 tables on Veracyte Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
186.77 %